Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

140.64 +3.56 (+2.60%)
Official Closing Price Updated: 4:15 PM EST, Feb 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
50 51 Next >
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
Here's What's Next For Biohaven After Its $12 Billion Pfizer Buyout, According To CEO Vlad Coric
The company that remains still has a large pipeline of non-migraine assets. 
Via Investor's Business Daily
Is Biogen Stock a Buy Now?
Its new drug might succeed where the company faltered in 2021. 
Via The Motley Fool
Where Biogen Stands With Analysts
Via Benzinga
FDA Rejects Eli Lilly's Donanemab For Alzheimer's Disease, Needs More Data
Via Benzinga
The 7 Most Undervalued Nasdaq Stocks to Buy in February 2023
For those seeking the best discounts in the tech-centered index, these are the most undervalued Nasdaq stocks to buy. 
Via InvestorPlace
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new... 
Via Benzinga
7 CRISPR Stocks With the Best Long-Term Potential
CRISPR stocks are becoming commercially viable leading to substantial returns in 2023 and beyond, as the technology will only improve. 
Via InvestorPlace
Cassava Sciences Stock Undervalued with Its $124 Price Target?
Casava Sciences Inc (NASDAQ: SAVA) stock has been the topic of much controversy in its quest for FDA approval for its simufilam drug. The Company is a 
Via MarketBeat
Exposures Product Safety
$100 Invested In Biogen 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Lecanemab Receives Priority Review Status in Japan
From Biogen Inc.
Via GlobeNewswire
Marketing Authorization Application for Lecanemab as Treatment for Early Alzheimer’s Disease Accepted by European Medicines Agency
From Biogen Inc.
Via GlobeNewswire
Is Biogen Stock a No-Brainer Buy After Eli Lilly's Alzheimer's Disease Setback?
Lilly's FDA rejection puts Biogen and its partner Eisai in the driver's seat in the Alzheimer's disease drug market. 
Via The Motley Fool
In A Stunner, Eli Lilly Stock Falls After FDA Delivers A Blow To Its Alzheimer's Drug
The company will need to complete its confirmatory study before asking for approval. 
Via Investor's Business Daily
Tech Stocks Get Netflix Boost Amid Jittery Wider Market On Friday, Dow Stares At 4th Straight Loss
U.S. stocks look set for a positive start on Friday, reversing course from the sell-off seen in the past three sessions. What Happened: Traders may have to contend with Fed speeches and housing market... 
Via Benzinga
Why Biogen's Stock Isn't Soaring Since Its Alzheimer's Drug Got Approval
The Food and Drug Administration authorized Leqembi under an accelerated approval pathway this month. 
Via The Motley Fool
If You Invested $25,000 in Biogen in 2018, This Is How Much You Would Have Today
The stock hasn't been a great investment in recent years, but there's hope for a brighter future. 
Via The Motley Fool
Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen
Via Benzinga
This Monumental Breakthrough Could Turn the World Upside Down -- and Make Some Investors Filthy Rich
The fountain of youth might not be a myth in the future. 
Via The Motley Fool
Elliott Wave Technical Analysis: Biogen Inc.
We are looking for further downside into wave C which could take us back to the area of wave 4. 
Via Talk Markets
1 Hot Growth Stock to Buy Now, and 1 to Avoid
One company is gearing up for further growth while the other stumbles over itself. 
Via The Motley Fool
Biotech Bonanza: 2023 Biotech Outlook As The Fed Remains Hawkish
2023 can be the year of biotechs after two consecutive years of negative or barely positive returns. 
Via Talk Markets
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
There's more to the story with Biogen after receiving good news for Leqembi. 
Via The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read. 
Via Benzinga
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.  
Via Benzinga
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to 
Via Benzinga
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
Via Benzinga
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock. 
Via InvestorPlace
Top Picks For 2023: Anavex Life Sciences
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett... 
Via Talk Markets
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
50 51 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.